NASDAQ:BIIBBiogen Stock Price, Forecast & News

Biogen's stock was trading at $294.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BIIB stock has increased by 2.0% and is now trading at $300.26.
View which stocks have been most impacted by Coronavirus.

31 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 4 sell ratings, 16 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Biogen.

Biogen is scheduled to release its next quarterly earnings announcement on Tuesday, October 27th 2020.
View our earnings forecast for Biogen.

Biogen Inc (NASDAQ:BIIB) issued its quarterly earnings data on Wednesday, July, 22nd. The biotechnology company reported $10.26 earnings per share for the quarter, topping analysts' consensus estimates of $8.03 by $2.23. The biotechnology company earned $3.68 billion during the quarter, compared to analysts' expectations of $3.44 billion. Biogen had a return on equity of 50.10% and a net margin of 40.91%. During the same period last year, the business posted $9.15 earnings per share.
View Biogen's earnings history.

Biogen declared that its Board of Directors has authorized a share repurchase plan on Monday, December 23rd 2019, which allows the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Shares buyback plans are often an indication that the company's leadership believes its shares are undervalued.

Biogen updated its FY20 earnings guidance on Wednesday, July, 22nd. The company provided earnings per share guidance of $34.00-36.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $31.98. The company issued revenue guidance of $13.8-14.2 billion, compared to the consensus revenue estimate of $13.90 billion.

31 brokers have issued 1 year target prices for Biogen's shares. Their forecasts range from $228.00 to $410.00. On average, they anticipate Biogen's stock price to reach $312.79 in the next twelve months. This suggests a possible upside of 4.2% from the stock's current price.
View analysts' price targets for Biogen.

News stories about BIIB stock have trended somewhat negative this week, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Biogen earned a media sentiment score of -1.9 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days.
View the latest news about Biogen.

Biogen saw a drop in short interest in January. As of January 15th, there was short interest totaling 3,600,000 shares, a drop of 16.9% from the December 31st total of 4,330,000 shares. Based on an average daily volume of 1,790,000 shares, the days-to-cover ratio is presently 2.0 days. Approximately 2.0% of the company's stock are short sold.
View Biogen's Short Interest.

Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Novavax (NVAX), Immunomedics (IMMU) and Repligen (RGEN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Walt Disney (DIS), Amgen (AMGN), Micron Technology (MU), Intel (INTC) and Boeing (BA).

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Biogen's stock is owned by many different institutional and retail investors. Top institutional investors include LSV Asset Management (0.64%), Sumitomo Mitsui Trust Holdings Inc. (0.48%), Swiss National Bank (0.43%), Robeco Institutional Asset Management B.V. (0.25%), First Trust Advisors LP (0.24%) and New York State Common Retirement Fund (0.23%). Company insiders that own Biogen stock include Alexander J Denner, Brian S Posner, Michael D Ehlers, Michel Vounatsos, Robert W Pangia and Stephen A Sherwin.
View institutional ownership trends for Biogen.

BIIB stock was sold by a variety of institutional investors in the last quarter, including Banco Santander S.A., Toronto Dominion Bank, Russell Investments Group Ltd., First Trust Advisors LP, LSV Asset Management, Ziegler Capital Management LLC, Candriam Luxembourg S.C.A., and New York State Common Retirement Fund. Company insiders that have sold Biogen company stock in the last year include Brian S Posner, and Stephen A Sherwin.
View insider buying and selling activity for Biogen.

BIIB stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., PGGM Investments, Robeco Institutional Asset Management B.V., SG Americas Securities LLC, MERIAN GLOBAL INVESTORS UK Ltd, State of Michigan Retirement System, QCI Asset Management Inc. NY, and First Eagle Investment Management LLC. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner, and Michel Vounatsos.
View insider buying and selling activity for Biogen.

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BIIB stock can currently be purchased for approximately $300.26.

Biogen has a market capitalization of $47.54 billion and generates $14.38 billion in revenue each year. The biotechnology company earns $5.89 billion in net income (profit) each year or $33.57 on an earnings per share basis. Biogen employs 7,400 workers across the globe.

The official website for Biogen is www.biogen.com.

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]